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Abstract
Purpose To evaluate the effect of once daily admin-
istration of chitosan-N-acetylcysteine (Lacrimera) in
the management of dry eye disease (DED).
Methods Eighteen patients (3 male, 15 female) aged
25–86 years (mean 61.1) and suffering from moderate
to severe DED with superficial punctate keratitis
(SPK) were retrospectively evaluated after a trial of
Lacrimera drops (1 drop in the morning for 5 days
only). All the patients were using other artificial tears
before the treatment. All lubricants were stopped, and
Lacrimera was started instead. Slit-lamp examina-
tion and images were taken before and at 1 and
3 weeks follow-up after the treatment. The subjective
(Ocular Surface Disease Index, OSDI) and objective
(Oxford Grading System, OGS) evaluation was
recorded. A paired student’s t test was performed to
analyse the data.
Results At baseline, the SPK grade was I to IV
(OGS) and the OSDI ranged from 25 to 71.4. Fifteen
patients showed a statistically significant (p\ 0.0001)
improvement in OGS and the OSDI at 3 weeks post-
treatment. Three patients showed no improvement.
Conclusions A single-dose instillation of chitosan-
N-acetylcysteine for five consecutive days improved
signs and symptoms in patients affected from DED
from a variety of causes, who were refractory to
standard treatment with lubricants. Given its posology,
the absence of side effects and the results obtained
Lacrimera should be taken into consideration as a
viable option in patients with moderate to severe DED.
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Introduction
Dry eyes disease (DED) is a common condition. There
are many factors that can lead to symptoms of
discomfort, visual disturbance and tear film instability
with potential damage to the ocular surface (OS) [1].
Considering the global prevalence, DED is a public
health issue with huge clinical and economic impact.
Health and integrity of the OS-lacrimal functional
unit (LFU), which is composed of the cornea,
conjunctiva, accessory lacrimal and meibomian
glands, the main lacrimal glands, the blink mechanism
and the sensory (via the trigeminal nerve to the central
nervous system) and motor nerves (sympathetic and
parasympathetic fibres) [2], is critical for sight.
Classically, the tear film is composed of three
layers, mucin, aqueous and lipid, though latterly the
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distinction between the mucin and aqueous layers is
reported to be less well defined with the two merging
in a gradient rather than as distinct layers. Maintaining
a healthy and comfortable ocular surface requires
stability of the whole system. A malfunction of any of
the LFU components can lead to DED.
Typically, DED is divided into two subtypes:
aqueous tear-deficient dry eye (ADDE) and evapora-
tive dry eye (EDE). The diagnosis of DED is based on
clinical history and symptoms supported by a number
of tests that can provide additional information. The
diagnosis is often a challenge on account of the
disconnect between symptoms and signs, which often
do not correlate and the overlap between normal and
abnormal values of the diagnostic tests such as
Schirmer’s test, tear film break-up time and tear
meniscus height. Tear osmolarity has been proposed
as being more specific, but clinical experience shows
that even with this test there is an overlap with some
symptomatic patients having low osmolarity and vice
versa [3].
Treatment options for DED are multiple and
manifold, reflecting the challenge posed by a disease
of varied etiology, complex pathology and symptoma-
tology. Artificial tear drops are the mainstay. These
provide relief, but this is often temporary requiring
frequent instillation of drops, which in turn impacts on
the quality of life (QoL) and compliance. Inflammation
has been identified as a major underlying factor in
DED, and topical short-term steroids or long-term non-
steroidal anti-inflammatory drops, namely cyclospor-
ine 0.05–0.1%, have gained prominence in the therapy
of DED. Interventions such as punctal occlusion with
plugs or cautery, contact lenses and tarsorrhaphy are
options in severe and refractory cases [4–8].
In this retrospective study, we evaluated the
efficiency of the dry eye medication Lacrimera [9],
which requires only once-a-day instillation, (CROMA-
PHARMA GmbH, 2100, Leobendorf, Austria) in the
management of the DED. Lacrimera is based on a
chitosan biopolymeric backbone, which is modified by
the introduction of N-acetylcysteine (NAC) via nucle-
ophilic substitution.
Chitosan is a well-characterised polycationic
polysaccharide derived from alkaline deacylation of
chitin and exhibits low toxicity and excellent biocom-
patibility. N-acetylcysteine, which is a derivative of
amino acid L-cysteine, also has been used to treat
corneal and external eye diseases [9].
Methods
Eighteen patients (3 males, 15 females) with moderate
to severe DED were treated with Lacrimera. Their
age ranged from 25 to 86 years (mean 61.1). All
patients had SPK (Table 1) and were already using
artificial tears with no or minimal benefit in both
symptoms and signs. Slit-lamp evaluation (Haag Streit,
Edinburgh Way, Harlow, Essex, UK) and images
(Topcon Great Britain Ltd., Kenneth Side, Newbury
Berkshire, UK) with yellow barrier filter were taken for
all patients before and 1 and 3 weeks after treatment. A
subjective (Ocular Surface Disease Index, OSDI) and
objective (Oxford Grading System, OGS) evaluation
was carried out in all patients at baseline and after use
of Lacrimera. Statistical analysis for OSDI between
pre- and post-treatment group (3 weeks) was per-
formed with paired student’s t test using graph pad
prism software version 7.0 (Graph Pad, Inc.).
Treatment regime All concomitant artificial tear
drops were discontinued and Lacrimera administered
once a day, to each eye for 5 days only. Patients were
requested to record the daily administration of med-
ication and bring back any unused vials.
Results
At baseline, the SPK grade was I to IV (OGS) and the
OSDI ranged from 25 (mild) to 71.4 (severe) (Table 1).
After 3 weeks, there was a significant improvement in
the OSDI and OGS in 15 patients: p\ 0.0001 with
mean difference of 18.11 and 95% confidence interval
ranging from 11.46 to 24.77. In all the 15 cases, the
improvement was noted in both the OSDI and OGS
(Fig. 1). In three patients, no improvement was noted,
neither in the OSDI nor in the OGS (Table 1). All
patients had used the drops as prescribed but not
consistently at the same time every day.
Discussion
Among the different treatment options available on the
market for DED and ocular surface disease, lubricants
and anti-inflammatory drugs are undoubtedly the most
frequently used products. Lubricants, however, can
only suppress symptoms temporarily. It is well known
though that chronic use/abuse of topical steroids can
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lead to severe side effects such as cataract and
glaucoma.
In our cases, we ascertained the efficiency of
chitosan-N-acetylcysteine eye drops (Lacrimera) in
the management of SPK in eyes with different
backgrounds and we based our findings on the OSDI
and OGS. OSDI has been proven to be a reliable
questionnaire in assessing the severity of ocular surface
symptoms (from mild to severe) [10], and the OGS is
Table 1 Patient demographics, diagnosis and severity of dry eye disease pre and post treatment
General information OSDI OGS




1 62 F Granular dystrophy, corneal grafts 62.5 31.3 III I
2 58 M Persistent epithelial defect, glaucoma 55.6 41.7 II I
3 81 M Ocular cicatricial pemphigoid, persistent epithelial defect 53.6 35.7 III II
4 79 F Glaucoma 46.9 31,3 II I
5 58 F Lasik 71.4 17.9 IV 0
6 49 F Rheumatoid arthritis 35.7 17.9 II I
7 52 M Epithelial defect, Neurotrophic keratopathy 25 12.5 I 0
8 74 F Superior limbic keratitis 22.7 11.4 II I
9 83 F Rheumatoid arthritis 50 25 III I
10 69 F Dry eyes 45.5 11.4 III 0
11 81 F Ocular cicatricial pemphigoid, glaucoma, dry eyes 55.6 41.7 II I
12 86 F Interstitial keratitis 55.6 55.6 III III
13 25 F Corneal graft, dry eyes 46.9 31.3 III II
14 36 F Neurotrophic keratopathy 46.9 46.9 II II
15 54 F Limbal stem cell deficiency 41.7 41.7 II II
16 63 F Corneal decompensation 37.5 25 II I
17 54 F Glaucoma 46.9 15.6 III 0
18 36 F Neurotrophic keratopathy 41.7 21.8 II I
OSDI Ocular Surface Disease Index, OGS Oxford Grade System, F female, M male
Fig. 1 Slit-lamp images taken with diffuse illumination and yellow barrier filter showing corneal fluorescein staining of different grade
in four different patients (4, 9, 10 and 17 in Table 1) before (a, c, e, g) and after (b, d, f, h) treatment with Lacrimeradrops
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widely used as an effective objective indicator of DED
signs.
We found that Lacrimera was able to reduce signs
and symptoms in most of our cases with good
compliance and tolerability, despite the varied nature
of the underlying cause. No adverse events were
recorded over the 3-week period. This data confirms
findings of a recently published clinical study with
Lacrimera in dry eye patients [9] but also suggests
that the indications for use of Lacrimera can be
expanded to other ocular surface pathology associated
with dry eyes. We found the ocular surface to be
healthier 1 week after treatment as indicated by
significant reduction of SPK in severe dry eye patients.
This treatment is meant to be efficient for up to
3 weeks after stopping the drops after 5 days applica-
tion. Recent clinical data from this study indicate
special properties of chitosan-N-acetylcysteine eye
drops, which help to form a long-lasting protective
layer on the ocular surface for up to 3 weeks, thus
stabilising and restoring the tear film. New biopolymer
technology on which Lacrimera is based may over-
come limitations of artificial tears by interacting with
the polymer–mucin network on the ocular surface. In
particular, covalent interactions of free thiol moieties
originating from chitosan-N-acetylcysteine and from
mucosal glycoproteins produce an artificial glycoca-
lyx-like structure on the eye. This in turn may lead to an
enhanced stability of the polymer–mucin network [9].
Having to apply only one drop per day and for only
5 days, not only will lead to better compliance and
quality of life but can also reduce the cost of
management. In dry eyes, including some associated
with a diverse range of pathology such as corneal
grafts, glaucoma and glaucoma medication-related dry
eyes, corneal dystrophy and others listed in Table 1,
Lacrimera worked very well in reducing both signs
and symptoms. The three cases that did not respond
had limbal stem cell deficiency, neurotrophic ker-
atopathy and interstitial keratitis, respectively. This
might be a reflection of the underlying condition
where the pathology is more complex and the corneal
epithelium is more vulnerable.
It is likely that patients would continue to benefit
from use of Lacrimera on an ongoing basis beyond
the 3-week period tested in this study. Further studies
need to be carried out in order to confirm the efficacy
and safety of the use of Lacrimera over a longer
duration, in larger number of patients, for each
underlying pathology tested. Many patients had
requested a second course of the medical device and
given the results obtained Lacrimera should be taken
into consideration as a viable option in patients with
moderate to severe DED.
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